The FDA says it expects more boards to join an inter-regulatory API (active pharmaceutical ingredient) inspection programme after simplifying the sign-up process.
Ideal Cures has been granted a US patent for an immediate release film coating tech that - it claims - could rid the Pharma production sector of solvents.
GSK has made good on its promise to invest in the UK, confirming plans to spend £500m ($789m) on new manufacturing capacity in the country just a day after the Government introduced a tax ‘patent box.'
Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
Indian API manufacturers may dominate the list of companies that have had CEPs suspended this year, but that may say more about inspection policies than it does about standards outside Europe.
Generic API (active pharmaceutical ingredient) makers should consider the off-patent potential of a drug as soon as it is launched, according to a new study by PharmaIntellect.
Generics and API maker Ranbaxy has opened a plant in Casablanca, Morocco in a bid to strengthen its foothold in the “increasingly important” North African drugs market.
GlaxoSmithKline (GSK) and Astrazeneca have each funded new nuclear magnetic resonance (NMR) research at the University of Warwick, UK which could improve the QC process for drugsmakers.
Regulation over combination products must be simplified to get products to market quicker, said Marielle Fournier, director of Voisin Life Sciences Consulting.
Researchers are calling for alternative excipients for vegetarians who are unwittingly consuming animal fats when physicians prescribe meds containing gelatin.
Abbott Laboratories will pump €85m ($113m) into the expansion of its API production plant in Sligo, Ireland, in preparation of the launch of its pipeline products.
Lonza has denied reports it has signed a deal with the South African government to build a $210m (€159m) API plant, saying it is merely “in discussions” over plans.
Prismic Pharmaceuticals is hunting for alliances to help it bring a more efficient anti-psychotic to the market after acquiring assets from drug manufacturer Scarista.
AMRI posted a Q4 loss on lower sales but predicts that contracting revenues and margins will increase in 2012 thanks to cost cutting measures and new contracts
Pharma supply chain consortium Rx-360 has advised drugmakers to check their L-Arginine stocks, warning that a recent surge in demand could limit supplies.
Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.
